APA (7th ed.) Citation

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., . . . Tallman, M. S. (2017). Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood, 130(6), 722-731. https://doi.org/10.1182/blood-2017-04-779405

Chicago Style (17th ed.) Citation

Stein, Eytan M., et al. "Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia." Blood 130, no. 6 (2017): 722-731. https://doi.org/10.1182/blood-2017-04-779405.

MLA (9th ed.) Citation

Stein, Eytan M., et al. "Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia." Blood, vol. 130, no. 6, 2017, pp. 722-731, https://doi.org/10.1182/blood-2017-04-779405.